vs

Side-by-side financial comparison of NETSCOUT SYSTEMS INC (NTCT) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

NETSCOUT SYSTEMS INC is the larger business by last-quarter revenue ($250.7M vs $140.6M, roughly 1.8× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs 22.0%, a 7.3% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs -0.5%). NETSCOUT SYSTEMS INC produced more free cash flow last quarter ($59.3M vs $48.8M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs 11.0%).

NETSCOUT Systems, Inc. is an American technology company that specializes in software observability, deep packet inspection, DDoS mitigation and AIOps. Headquartered in Westford, Massachusetts, the company was founded in 1984 by Anil Singhal and Narendra Popat, originally under the name Frontier Software.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

NTCT vs VCYT — Head-to-Head

Bigger by revenue
NTCT
NTCT
1.8× larger
NTCT
$250.7M
$140.6M
VCYT
Growing faster (revenue YoY)
VCYT
VCYT
+19.1% gap
VCYT
18.5%
-0.5%
NTCT
Higher net margin
VCYT
VCYT
7.3% more per $
VCYT
29.3%
22.0%
NTCT
More free cash flow
NTCT
NTCT
$10.5M more FCF
NTCT
$59.3M
$48.8M
VCYT
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
11.0%
NTCT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
NTCT
NTCT
VCYT
VCYT
Revenue
$250.7M
$140.6M
Net Profit
$55.1M
$41.1M
Gross Margin
81.6%
72.5%
Operating Margin
25.7%
26.4%
Net Margin
22.0%
29.3%
Revenue YoY
-0.5%
18.5%
Net Profit YoY
13.0%
704.8%
EPS (diluted)
$0.75
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NTCT
NTCT
VCYT
VCYT
Q4 25
$250.7M
$140.6M
Q3 25
$219.0M
$131.9M
Q2 25
$186.7M
$130.2M
Q1 25
$205.0M
$114.5M
Q4 24
$252.0M
$118.6M
Q3 24
$191.1M
$115.9M
Q2 24
$174.6M
$114.4M
Q1 24
$203.4M
$96.8M
Net Profit
NTCT
NTCT
VCYT
VCYT
Q4 25
$55.1M
$41.1M
Q3 25
$25.8M
$19.1M
Q2 25
$-3.7M
$-980.0K
Q1 25
$18.6M
$7.0M
Q4 24
$48.8M
$5.1M
Q3 24
$9.0M
$15.2M
Q2 24
$-443.4M
$5.7M
Q1 24
$-32.4M
$-1.9M
Gross Margin
NTCT
NTCT
VCYT
VCYT
Q4 25
81.6%
72.5%
Q3 25
80.1%
69.2%
Q2 25
76.7%
69.0%
Q1 25
77.7%
69.5%
Q4 24
81.5%
66.4%
Q3 24
78.0%
68.2%
Q2 24
74.6%
68.1%
Q1 24
75.3%
64.5%
Operating Margin
NTCT
NTCT
VCYT
VCYT
Q4 25
25.7%
26.4%
Q3 25
14.8%
17.4%
Q2 25
-3.5%
-4.0%
Q1 25
9.7%
2.5%
Q4 24
24.5%
3.5%
Q3 24
7.4%
10.4%
Q2 24
-265.4%
4.0%
Q1 24
-18.2%
-4.8%
Net Margin
NTCT
NTCT
VCYT
VCYT
Q4 25
22.0%
29.3%
Q3 25
11.8%
14.5%
Q2 25
-2.0%
-0.8%
Q1 25
9.1%
6.2%
Q4 24
19.4%
4.3%
Q3 24
4.7%
13.1%
Q2 24
-254.0%
5.0%
Q1 24
-15.9%
-1.9%
EPS (diluted)
NTCT
NTCT
VCYT
VCYT
Q4 25
$0.75
$0.50
Q3 25
$0.35
$0.24
Q2 25
$-0.05
$-0.01
Q1 25
$0.28
$0.09
Q4 24
$0.67
$0.07
Q3 24
$0.13
$0.19
Q2 24
$-6.20
$0.07
Q1 24
$-0.43
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NTCT
NTCT
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$540.6M
$362.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.6B
$1.3B
Total Assets
$2.3B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NTCT
NTCT
VCYT
VCYT
Q4 25
$540.6M
$362.6M
Q3 25
$483.4M
$315.6M
Q2 25
$489.6M
$219.5M
Q1 25
$457.4M
$186.1M
Q4 24
$398.4M
$239.1M
Q3 24
$363.4M
$274.1M
Q2 24
$362.2M
$235.9M
Q1 24
$389.7M
$209.2M
Stockholders' Equity
NTCT
NTCT
VCYT
VCYT
Q4 25
$1.6B
$1.3B
Q3 25
$1.6B
$1.3B
Q2 25
$1.5B
$1.2B
Q1 25
$1.6B
$1.2B
Q4 24
$1.5B
$1.2B
Q3 24
$1.5B
$1.2B
Q2 24
$1.4B
$1.1B
Q1 24
$1.9B
$1.1B
Total Assets
NTCT
NTCT
VCYT
VCYT
Q4 25
$2.3B
$1.4B
Q3 25
$2.2B
$1.4B
Q2 25
$2.2B
$1.3B
Q1 25
$2.2B
$1.3B
Q4 24
$2.2B
$1.3B
Q3 24
$2.1B
$1.3B
Q2 24
$2.1B
$1.2B
Q1 24
$2.6B
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NTCT
NTCT
VCYT
VCYT
Operating Cash FlowLast quarter
$62.1M
$52.6M
Free Cash FlowOCF − Capex
$59.3M
$48.8M
FCF MarginFCF / Revenue
23.6%
34.7%
Capex IntensityCapex / Revenue
1.1%
2.7%
Cash ConversionOCF / Net Profit
1.13×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$275.5M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NTCT
NTCT
VCYT
VCYT
Q4 25
$62.1M
$52.6M
Q3 25
$6.7M
$44.8M
Q2 25
$73.6M
$33.6M
Q1 25
$141.5M
$5.4M
Q4 24
$41.5M
$24.5M
Q3 24
$-3.7M
$30.0M
Q2 24
$38.4M
$29.6M
Q1 24
$93.6M
$-9.0M
Free Cash Flow
NTCT
NTCT
VCYT
VCYT
Q4 25
$59.3M
$48.8M
Q3 25
$4.4M
$42.0M
Q2 25
$71.7M
$32.3M
Q1 25
$140.1M
$3.5M
Q4 24
$39.6M
$20.4M
Q3 24
$-4.6M
$27.7M
Q2 24
$37.2M
$26.8M
Q1 24
$92.0M
$-11.1M
FCF Margin
NTCT
NTCT
VCYT
VCYT
Q4 25
23.6%
34.7%
Q3 25
2.0%
31.8%
Q2 25
38.4%
24.8%
Q1 25
68.4%
3.1%
Q4 24
15.7%
17.2%
Q3 24
-2.4%
23.9%
Q2 24
21.3%
23.4%
Q1 24
45.2%
-11.5%
Capex Intensity
NTCT
NTCT
VCYT
VCYT
Q4 25
1.1%
2.7%
Q3 25
1.0%
2.1%
Q2 25
1.0%
1.0%
Q1 25
0.7%
1.6%
Q4 24
0.7%
3.5%
Q3 24
0.5%
1.9%
Q2 24
0.7%
2.4%
Q1 24
0.8%
2.2%
Cash Conversion
NTCT
NTCT
VCYT
VCYT
Q4 25
1.13×
1.28×
Q3 25
0.26×
2.34×
Q2 25
Q1 25
7.60×
0.76×
Q4 24
0.85×
4.80×
Q3 24
-0.41×
1.98×
Q2 24
5.16×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NTCT
NTCT

Services$129.0M51%
Products$121.7M49%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons